01276.HK
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 46.50
+0.74%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
29.4x
EV/EBITDA
—
Market Cap
HKD 308.63B
MomentumView details →
1D Return
+0.74%
YTD Return
−34.87%
RSI (14)
34.7
ValuationView details →
P/E (Fwd)
29.4x
EV/EBITDA
—
Market Cap
HKD 308.63B
RSI (14)
34.7
MomentumView details →
1D Return
+0.74%
YTD Return
−34.87%
Similar companies
Latest newsMore news →
Hengrui Medicine announced that its subsidiary Guangdong Hengrui Medicine received an acceptance notice from China's National Medical Products Administration for the marketing authorization application of its self-developed drug Zhuotuoqibei monoclonal antibody injection (SHR-1819), intended for treating moderate-to-severe atopic dermatitis in adults.1d agoHengrui Medicine's subsidiary Shandong Shengdi Pharmaceutical received acceptance from China's National Medical Products Administration for the marketing authorization application of HRS-7535 tablets, a novel oral small-molecule GLP-1R agonist for type 2 diabetes.2d agoHengrui Pharmaceuticals announced that its subsidiary Suzhou Shengdiya Biopharmaceutical's ADC drug Ruikang trastuzumab (SHR-A1811) met the primary endpoint in a Phase III clinical trial for first-line treatment of HER2-positive advanced breast cancer, and the company plans to submit a pre-marketing communication application to the CDE.4d ago